Table 4 Univariate and multivariate analyses of overall survival progression free survival.
(A) | |||||
|---|---|---|---|---|---|
Progression free survival | |||||
Univariate analysis | Multivariate analysis | ||||
Median survivala | HR (95% CI) | p valueb | HR (95% CI) | p valueb | |
Age (> 65 vs. ≤ 65) years | 8.4 vs. 9.6 | 1.05 (0.70–1.56) | 0.827 | ||
Sex (Male vs. Female) | 9.3 vs. 8.0 | 0.97 (0.65–1.44) | 0.870 | ||
BMI (≤ 18.5 vs. > 18.5) | 8.4 vs. 8.9 | 1.16 (0.77–1.72) | 0.479 | ||
Charlson Comorbidity Index (2 ≤ vs. 0 or 1) | 10.4 vs. 8.4 | 0.99 (0.61–1.63) | 0.984 | ||
Lauren classification (diffuse or Mixed vs. intestinal) | 8.4 vs. 8.9 | 0.98 (0.68–1.42) | 0.922 | ||
Macroscopic type (type 4 vs. other) | 5.0 vs. 8.9 | 1.39 (0.78–2.48) | 0.263 | ||
HER2 score (3 + vs. 2 +) | 8.7 vs. 8.4 | 0.85 (0.52–1.38) | 0.503 | ||
Regimen (Platinum drug ( +) vs. Platinum drug (–)) | 9.5 vs. 5.8 | 0.68 (0.42–1.10) | 0.119 | 0.72 (0.36–1.46) | 0.366 |
Number of metastatic sites (2 ≤ vs. 0–1) | 7.6 vs. 10.3 | 1.77 (1.22–2.56) | 0.003 | 1.80 (1.23–2.62) | 0.002 |
Previous chemotherapy (yes vs. no) | 6.0 vs. 9.3 | 1.40 (0.87–2.24) | 0.165 | 0.99 (0.50–1.97) | 0.983 |
Previous gastrectomy (yes vs. no) | 6.5 vs. 9.8 | 1.21 (0.82–1.78) | 0.339 | – | |
PTEN (loss vs. positive) | 6.4 vs. 10.0 | 1.70 (1.09–2.65) | 0.020 | 1.63 (1.04–2.57) | 0.035 |
(B) | |||||
|---|---|---|---|---|---|
Overall survival | |||||
Univariate analysis | Multivariate analysis | ||||
Median survivala | HR (95% CI) | p valueb | HR (95% CI) | p valueb | |
Age (> 65 vs. ≤ 65) years | 20.6 vs. 17.7 | 0.96 (0.61–1.51) | 0.863 | ||
Sex (Male vs. Female) | 19.6 vs. 16.9 | 0.98 (0.62–1.56) | 0.937 | ||
BMI (≤ 18.5 vs. > 18.5) | 17.7 vs. 20.3 | 1.24 (0.79–1.94) | 0.349 | ||
Charlson Comorbidity Index (2 ≤ vs. 0 or 1) | 21.0 vs. 19.2 | 1.00 (0.56–1.81) | 0.988 | ||
Lauren classification (diffuse or Mixed vs. intestinal) | 16.6 vs. 20.3 | 1.15 (0.75–1.77) | 0.507 | ||
Macroscopic type (type 4 vs. other) | 12.6 vs. 20.1 | 1.60 (0.80–3.19) | 0.185 | 2.13 (1.04–4.34) | 0.038 |
HER2 score (3 + vs. 2 +) | 18.2 vs. 22.6 | 1.06 (0.59–1.92) | 0.839 | ||
Regimen (Platinum drug ( +) vs. Platinum drug (–)) | 20.3 vs. 12.0 | 0.59 (0.35–1.00) | 0.049 | 0.63 (0.37–1.07) | 0.089 |
Number of metastatic sites (2 ≤ vs. 0–1) | 13.7 vs. 21.1 | 1.99 (1.30–3.04) | 0.002 | 2.05 (1.34–3.15) | 0.001 |
Previous chemotherapy (yes vs. no) | 14.5 vs. 19.6 | 1.39 (0.83–2.34) | 0.212 | ||
Previous gastrectomy (yes vs. no) | 19.2 vs. 20.6 | 1.07 (0.69–1.67) | 0.752 | – | |
PTEN (loss vs. positive) | 13.3 vs. 21.0 | 1.78 (1.08–2.94) | 0.023 | 1.83 (1.09–3.07) | 0.022 |
